Paul Vega

Senior Accountant at Turnstone Biologics

Paul Vega has a diverse work experience in various roles and industries. Paul has recently worked as a Senior Accountant at Turnstone Biologics since July 2022. Prior to that, they served as an Operations Manager at M&A Real Estate Partners since March 2017. From August 2017 to July 2022, Paul worked as an Accounting Manager at Myers-Stevens & Toohey & Co. Inc., a licensed insurance broker/administrator. Before that, they were a Senior Accountant at Anyone Home Inc from March 2015 to April 2017. Paul also worked as a Project Consultant at Irvine Company from April 2014 to March 2015. Additionally, they gained experience as an Investment Associate at Healthcare Real Estate Group from December 2012 to March 2014. Paul started their career as an Intern - Wealth Management at UBS from February 2012 to July 2012, where they assisted with client relations and performed data entry and analysis.

Paul Vega attended UC Irvine from 2008 to 2012, where they studied Economics and Spanish. Paul did not obtain a degree during their time at UC Irvine. In addition to their education at UC Irvine, Paul obtained certifications in the financial industry. In June 2013, they obtained the Series 63 - Uniform Securities Agent State Law Examination certification from the Financial Industry Regulatory Authority. In May 2013, they also obtained the Series 22 - Direct Participation Programs Limited Representative certification from the same institution. Prior to that, in August 2012, they obtained the Life, Accident & Health certification from the California Department of Insurance.

Location

Irvine, United States

Links

Previous companies


Org chart

No direct reports

Teams


Offices

This person is not in any offices


Turnstone Biologics

Turnstone Biologics, a privately held clinical stage biotech company, is developing breakthrough cancer immunotherapies by advancing two leading and complementary platforms that drive innate and adaptive tumor immunity, to provide benefit to the millions of cancer patients underserved by current treatment options.


Industries

Employees

51-200

Links